Ninlaro (ixazomib) — Medica
Systemic light chain amyloidosis
Initial criteria
- age ≥ 18 years
- patient has tried at least one other regimen for this condition (e.g., Darzalex, Darzalex Faspro, Kyprolis, bortezomib, lenalidomide, cyclophosphamide, or melphalan)
Approval duration
1 year